Article Versions Notes

Tummala T, Sevilla Uruchurtu AS, Cruz ADL, Huntington KE, George A, Liguori NR, Zhang L, Zhou L, Abbas AE, Azzoli CG, et al. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer. Current Oncology. 2023; 30(11):9611-9626. https://doi.org/10.3390/curroncol30110696

Tummala, Tej, Ashley Sanchez Sevilla Uruchurtu, Arielle De La Cruz, Kelsey E. Huntington, Andrew George, Nicholas R. Liguori, Leiqing Zhang, Lanlan Zhou, Abbas E. Abbas, Christopher G. Azzoli, and et al. 2023. "Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer" Current Oncology 30, no. 11: 9611-9626. https://doi.org/10.3390/curroncol30110696

Tummala, T., Sevilla Uruchurtu, A. S., Cruz, A. D. L., Huntington, K. E., George, A., Liguori, N. R., Zhang, L., Zhou, L., Abbas, A. E., Azzoli, C. G., & El-Deiry, W. S. (2023). Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer. Current Oncology, 30(11), 9611-9626. https://doi.org/10.3390/curroncol30110696